Children, particularly neonates, can be biologically more sensitive to the same toxicant on a body weight basis than adults. Current understanding of the rates of maturation of metabolism and evidence from case studies indicate that human infants up to 6 months of age typically lack the capacity to detoxify and eliminate substances as readily as adults. For most chemicals, the infant physiologic systems usually produce higher blood levels for longer periods. The newborn's metabolic capacity rapidly matures and, by 6 months of age, children are usually not more sensitive than adults based on their pharmacokinetic competence. Whether children are at greater risk from chemical exposures is another question. Drawing conclusions about the ability of the U.S. Environmental Protection Agency's intraspecies (UF H ) and database (UF D ) uncertainty factors to protect children on the basis of the modest data available is challenging. However, virtually all studies available suggest that a high percentage of the population, including children, is protected by using a 10fold UF H or by using a 3.16-fold factor each for toxicokinetic and toxicodynamic variability. Based on specific comparisons for newborns, infants, children, adults and those with severe disease, the population protected is between 60% and 100%, with the studies in larger populations that include sensitive individuals suggesting that the value is closer to 100%. UF D is likewise protective when used with databases that are missing substantive studies.
INTRODUCTION
Recently, concerns have been raised that current environmental chemical exposure regulatory guidelines are not sufficient to protect children. Children, particularly neonates under 6 months, can be more sensitive on a body weight basis than adults to the same toxicant exposure. This is indicated by current understanding of the rates of maturation of the metabolic capacity to remove toxicants and evidence from studies involving pharmaceuticals, drugs of abuse, environmental contaminants, and dietary and endogenous agents.
For example, the immaturity of the infant biotransformation, elimination, and other physiologic systems usually produces higher blood levels of some chemicals for a longer period. There is a metabolic capacity for most tested substances in the newborn, although it is quite low and immature for some chemicals. However, the newborn's metabolic capacity rapidly matures. By 6 months of age most metabolic systems are reasonably mature, becoming fully capable by one year of age. Children are not more sensitive to chemical toxicity than adults at six months. In some cases children are less sensitive than adults.
RESULTS AND DISCUSSION
There is little doubt that when chemical doses are high and the infant is a neonate or still in the womb there is significant cause for concern over potential differential toxicity. For example, newborns metabolize chloramphenicol at a rate 12-fold smaller than the rate of older children. Newborns in the 1950s contracted gray baby syndrome, which often progressed to circulatory collapse and death in some cases, when given chloramphemicol for certain refractory infections (Evans and Kleiman 1986) .
In contrast, chlorpyrifos metabolism in children and adults has been studied at both high-dose and environmentally comparable dose levels. These studies suggest that younger animals are more susceptible to acute, high-dose chlorpyrifos toxicity than older animals. However, age-related differences are not observed at lower levels of exposure that are more consistent with environmentally relevant doses (Mortenson 1996; Whitney et al. 1995; Moser and Padilla 1998; Mattsson et al. 2000; Shurdut et al. 1998; Pope and Liu 1997; Zheng et al. 2000) , or young animals for some effects are less sensitive (Table 1) .
Whether children are at greater risk from chemical exposure is another question. Risk depends on both inherent sensitivity and on exposure conditions. Most published studies, such as those on chloramphenical, only examine relatively high doses or chemicals that accumulate to high doses after repeated exposures. As the chlorpyrifos studies suggest, low environmental exposures are less likely to overwhelm developing detoxification and elimination mechanisms. If chemical exposure levels remain below those capable of overwhelming a child's metabolic detoxification systems and producing toxicity, children are likely at no greater risk than are adults.
The goal of chemical regulation is to effectively limit potential risks of chemical toxicity by limiting chemical exposure. An adequate margin of safety that protects the general population and its sensitive subgroups, including children, must 2 3  4 3  97  102  104  112  104  107  111  61  48  90  102  94  114  74  67  100  98  101  136  101  94  97  94  101  143  89  68  96  102  101  322  18  39  51  92  92  350  106  96  94  91  100  395  13  23  58  93  93  537  16  31  69  90  88  638  15  40  35  63  67  1450  3  8  17  16  28  1782  8  15  18  40  46  1974  5  12  17  13  24  2718  1  6  11  11  20 Source: Mattsson et al. 2000. be established to limit risk. Many regulatory agencies establish "safe" or "virtually safe" doses. These are established by identifying no-observed-adverse-effect-levels (NOAELs) and doses that elicited a specific rate of response, or benchmark dose (BMD), usually through laboratory animal testing. Animals can be useful predictors of chemical hazards to humans. Growth and development are compressed into a shorter period in animals, which makes interpretation of animal testing inherently more difficult. However, similar events occur in both humans and laboratory animals. Thus, testing that covers the full period of animal development can reasonably be considered an appropriate surrogate for human development.
In the U.S. Environmental Protection Agency's (USEPA's) experience, in order to generate a high degree of confidence in a safe exposure level for noncancer toxicity, or reference dose (RfD), the available toxicity studies should include at least the following: two mammalian chronic toxicity and two developmental toxicity studies by the appropriate route of exposure in different species and one adequate mammalian multi-generation reproductive toxicity study by the appropriate route of exposure. This experience is similar to other world health organizations. Unfortunately, a complete database is not always available when the RfD must be estimated. Because of this, USEPA scientists conducted research and concluded that if one of the several bioassays needed to establish a complete database is missing, an uncertainty factor to account for such missing data could be supported quantitatively (Dourson et al. 1992) . Because of this, the USEPA uses a database uncertainty factor, referred to as UF D , to account for missing studies, including the studies that test young animals mentioned above, or other studies considered necessary to fully determine the chemical's critical effect.
For the extra protection of children, some have proposed using an additional 10-fold factor, for example as required by the Food Quality Protection Act (FQPA). However, USEPA's understanding its UF D and the FQPA leads it to conclude that the same toxicity issues are being addressed (USEPA 2002) . Based on our review and analysis of these and other data, we agree with the USEPA position. For example, when chronic rat and dog studies are available but rat reproductive and developmental toxicity studies are missing, an uncertainty factor of 3 applied to the lower of the chronic rat or dog NOAEL accounts for ∼92% of lower NOAELs that could have been identified by missing bioassays. An uncertainty factor of 10 accounts for 98% of such occurrences. Thus, the use of UF D , when studies in younger animals are not available, is protective.
The USEPA also employs an uncertainty factor, referred to as UF H , to account for variability in response to toxicity between the population mean and highly sensitive subjects, such as children, within the human population. These differences in response using hypothetical data are illustrated in Figure 1 . Using real data, most comprehensive studies suggest that a high percentage of the population, including children, is protected by using a 10-fold uncertainty factor for human variability or by using a 3.16-fold variability each for toxicokinetic and toxicodynamic variability. Based on specific comparisons for newborns, infants, children, adults, and those with severe disease, the population protected is between 60% and 100%. Studies of larger populations that include sensitive individuals suggest that the value is closer to 100%. Several examples of such information are shown in Table 2 .
It can be challenging to derive conclusions concerning the adequacy of UF H and UF D when drawing from modest data. However, our analysis of data lead us to believe that the addition of uncertainty factors other than UF D and UF H to limit environmental chemical exposure, such as that suggested by the FQPA, is unlikely to provide significantly greater protection to children over 6 months of age for reasons including: the relative sensitivities of children and adults; the sensitivity and 
